Browse SOX5

Summary
SymbolSOX5
NameSRY (sex determining region Y)-box 5
Aliases L-SOX5; MGC35153; L-SOX5B; L-SOX5F; Transcription factor SOX-5
Chromosomal Location12p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00505 HMG (high mobility group) box
Function

Binds specifically to the DNA sequence 5'-AACAAT-3'. Activates transcription of COL2A1 and AGC1 in vitro.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0002062 chondrocyte differentiation
GO:0007405 neuroblast proliferation
GO:0008356 asymmetric cell division
GO:0017145 stem cell division
GO:0032330 regulation of chondrocyte differentiation
GO:0032332 positive regulation of chondrocyte differentiation
GO:0036445 neuronal stem cell division
GO:0045165 cell fate commitment
GO:0048103 somatic stem cell division
GO:0048863 stem cell differentiation
GO:0051216 cartilage development
GO:0055057 neuroblast division
GO:0055059 asymmetric neuroblast division
GO:0061035 regulation of cartilage development
GO:0061036 positive regulation of cartilage development
GO:0061351 neural precursor cell proliferation
GO:0061448 connective tissue development
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0072089 stem cell proliferation
GO:0072497 mesenchymal stem cell differentiation
GO:0098722 asymmetric stem cell division
GO:2000736 regulation of stem cell differentiation
GO:2000738 positive regulation of stem cell differentiation
GO:2000739 regulation of mesenchymal stem cell differentiation
GO:2000741 positive regulation of mesenchymal stem cell differentiation
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolSOX5
NameSRY (sex determining region Y)-box 5
Aliases L-SOX5; MGC35153; L-SOX5B; L-SOX5F; Transcription factor SOX-5
Chromosomal Location12p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SOX5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SOX5 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28687615GlioblastomaPromote immunityElevated levels of SOX5/6/21 promoted SVZ cells to exit the cell cycle, whereas genetic ablation of SOX5/6/21 dramatically increased the capacity of these cells to form glioma-like tumors in an oncogene-driven mouse brain tumor model. Consistently, restoring high levels of SOX5/6/21 in human primary glioblastoma cells enabled expression of CDK inhibitors and decreased p53 protein turnover, which blocked their tumorigenic capacity through cellular senescence and apoptosis.
Summary
SymbolSOX5
NameSRY (sex determining region Y)-box 5
Aliases L-SOX5; MGC35153; L-SOX5B; L-SOX5F; Transcription factor SOX-5
Chromosomal Location12p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SOX5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSOX5
NameSRY (sex determining region Y)-box 5
Aliases L-SOX5; MGC35153; L-SOX5B; L-SOX5F; Transcription factor SOX-5
Chromosomal Location12p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SOX5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0670.893
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0430.965
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1470.855
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2750.549
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2090.897
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.3610.853
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1320.811
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2780.839
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1380.917
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3270.553
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2280.0765
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1450.299
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SOX5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolSOX5
NameSRY (sex determining region Y)-box 5
Aliases L-SOX5; MGC35153; L-SOX5B; L-SOX5F; Transcription factor SOX-5
Chromosomal Location12p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SOX5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSOX5
NameSRY (sex determining region Y)-box 5
Aliases L-SOX5; MGC35153; L-SOX5B; L-SOX5F; Transcription factor SOX-5
Chromosomal Location12p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SOX5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SOX5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSOX5
NameSRY (sex determining region Y)-box 5
Aliases L-SOX5; MGC35153; L-SOX5B; L-SOX5F; Transcription factor SOX-5
Chromosomal Location12p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SOX5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSOX5
NameSRY (sex determining region Y)-box 5
Aliases L-SOX5; MGC35153; L-SOX5B; L-SOX5F; Transcription factor SOX-5
Chromosomal Location12p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SOX5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSOX5
NameSRY (sex determining region Y)-box 5
Aliases L-SOX5; MGC35153; L-SOX5B; L-SOX5F; Transcription factor SOX-5
Chromosomal Location12p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SOX5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSOX5
NameSRY (sex determining region Y)-box 5
Aliases L-SOX5; MGC35153; L-SOX5B; L-SOX5F; Transcription factor SOX-5
Chromosomal Location12p12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SOX5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.